New Insights into the Inhibition of Human Neutrophil Elastase by Heparin.
From: Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Biochemistry
- Publish Date: Aug 2006
- ISSN: 0006-2960
- Volume: 45
- Issue: 30
- Pages: 9104-20
- Medium: Print
- Language: English
- Citation (JAMA): Spencer Jean L, Stone Phillip J, Nugent Matthew A, et al. New Insights into the Inhibition of Human Neutrophil Elastase by Heparin.. Biochemistry Aug 2006;45:9104-20
Abstract
In the normal feedback mechanism of injury and repair in the lung, fragmented heparan sulfate proteoglycans (HSPGs) from damaged extracellular matrix and cells are believed to interact with elastases to limit their activity. An imbalance in the HSPG-elastase response may play an important role in situations where uncontrolled lung injury leads to diseases such as emphysema. To gain insight into this complex process of heparin and heparan sulfate regulation of elastases, an experimental study was undertaken to resolve the mechanism and structural requirements of heparin inhibition of human neutrophil elastase (HNE). Kinetic analyses were completed using in vitro assays with synthetic and insoluble elastin substrates in the presence of HNE and various heparin preparations (14-15 kDa; 17-19 kDa), heparin-derived oligosaccharides (4-22 saccharides), and chemically modified heparins (2-O-, 6-O-, O-, and N-desulfated). Results showed that heparin inhibits HNE by a tight-binding, hyperbolic, competitive mechanism, contrary to previous reports in the literature. A minimum length of at least 12-14 saccharides is required for inhibition, after which inhibitory activity increases with chain length (or molecular mass). Although all N- and O-sulfate groups contribute to inhibition, 2-O-sulfate groups are less critical than either N- or 6-O-sulfate groups, indicating that inhibitory activity is dependent upon the heparin fine structure. Molecular-docking simulations support the kinetic results and provide a plausible model for the size requirement, whereby positively charged, clamp-like regions at the ends of the interdomain crevice (elastase fold) are used by heparin to bridge the active site and inhibit activity.
Mesh Headings (Keywords): Animals, Binding Sites, Dose-Response Relationship, Drug, Elastin, Heparin, Humans, Hydrolysis, Leukocyte Elastase, Oligosaccharides, Protein Structure, Secondary, Serine Proteinase Inhibitors, Substrate Specificity, Swine
Check for Full Text / PubMed Unique Identifier (PMID): 16866356
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.